一个月内三家,医疗巨头为何频频进行业务拆分

第一财经
23 May

近日,全球医疗器械巨头美敦力和制药巨头三星生物都宣布了新一轮的拆分计划,旨在聚焦高增长领域,并期待获得资本市场的更多认可。当地时间5月21日,美敦力宣布将拆分糖尿病业务部门,并成立独立公司。5月22日美股收盘,美敦力股价下跌超过4%。当地时间5月22日,三星生物宣布将拆分生物类似药业务,并成立新的控股公司。就在两周前,另一家医疗器械公司麦克森(McKesson)也宣布,计划将医疗外科业务部门拆分为...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10